Published in J Clin Endocrinol Metab on November 09, 2004
Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev (2012) 1.05
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol (2014) 0.95
Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med (2012) 0.94
Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag (2007) 0.93
Obesity differentially affects phenotypes of polycystic ovary syndrome. Int J Endocrinol (2012) 0.85
Medical management of metabolic dysfunction in PCOS. Steroids (2011) 0.81
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet (2011) 0.80
Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab (2010) 0.77
Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J Obes (2010) 0.77
Late pregnancy complications in polycystic ovarian syndrome. Hippokratia (2006) 0.76
Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reprod Sci (2015) 0.75
Use of computer terminals on wards to access emergency test results: a retrospective audit. BMJ (2001) 3.32
Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med (2007) 2.06
For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med (2010) 1.85
Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract (2009) 1.83
The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab (2003) 1.72
Evaluation of glycaemic control limits using the Ames DCA 2000 HbA1c analyser. Diabet Med (1993) 1.72
Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: a case for "tissue thyrotoxicosis". Br Med J (Clin Res Ed) (1984) 1.57
Biochemical screening for Down's syndrome. BMJ (1991) 1.56
Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res (1999) 1.55
Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer (1998) 1.51
Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia (2007) 1.49
Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormone. Clin Endocrinol (Oxf) (1993) 1.49
Hyperthyroidism secondary to a pituitary adenoma secreting TSH, FSH, alpha-subunit and GH. Clin Endocrinol (Oxf) (1994) 1.47
Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia (2007) 1.46
Neuroleptic malignant syndrome after venlafaxine. Lancet (2000) 1.45
Intra-operative parathyroid hormone monitoring in secondary hyperparathyroidism: is it useful? Clin Otolaryngol (2006) 1.44
Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res (1999) 1.41
Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem (1998) 1.39
CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) (2000) 1.37
Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia (2009) 1.30
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab (2002) 1.18
Fluvastatin induces apoptosis of vascular endothelial cells: blockade by glucocorticoids. Cardiovasc Surg (2003) 1.16
Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol (2002) 1.12
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) (2007) 1.09
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer (2005) 1.09
Estimations of gestational age and screening for Down's syndrome. BMJ (1991) 1.08
Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer (1999) 1.06
High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. Diabet Med (2010) 1.04
HbA1c measurement. J Clin Pathol (2004) 1.02
Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. J Clin Endocrinol Metab (2000) 1.02
The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract (1989) 1.01
Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances. Br J Radiol (2014) 1.00
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) (2008) 0.98
Transfer factor for carbon monoxide in patients with diabetes with and without microangiopathy. Thorax (1988) 0.98
The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br J Biomed Sci (2008) 0.97
Do ribosomopathies explain some cases of common variable immunodeficiency? Clin Exp Immunol (2010) 0.95
Intra-operative blood glucose measurements. The effect of haematocrit on glucose test strips. Anaesthesia (1994) 0.94
Increased insulin requirement in a patient with type 1 diabetes on rifampicin. Diabet Med (1993) 0.93
Investigation into possible causes of interference in serum testosterone measurement in women. Ann Clin Biochem (2006) 0.92
Insulin resistance and free androgen index correlate with the outcome of controlled ovarian hyperstimulation in non-PCOS women undergoing IVF. Hum Reprod (2009) 0.91
Detection of microvascular impairment in type I diabetics by laser Doppler flowmetry. Clin Physiol (1992) 0.91
How we do it: surgery should be considered equally with I131 and thionamide treatment as first-line therapy for thyrotoxicosis. Clin Otolaryngol (2006) 0.91
The relationship between mean glucose and HbA1c in premenopausal women compared with males in the Diabetes Control and Complications Trial. Diabet Med (2007) 0.89
Popliteal vein thrombosis associated with femoral osteochondroma and popliteal artery pseudoaneurysm. Postgrad Med J (1995) 0.89
Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. Ann Clin Biochem (1998) 0.88
Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database. Diabet Med (2012) 0.88
A comparison of methods for the measurement of 8-isoPGF(2α): a marker of oxidative stress. Ann Clin Biochem (2011) 0.88
Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. J Steroid Biochem Mol Biol (1998) 0.87
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab (2013) 0.87
Does thyroid subspecialization alter practice and outcome? A completed 4-year audit loop. Clin Otolaryngol (2005) 0.86
Gliclazide: a general free radical scavenger. Eur J Pharmacol (1991) 0.86
The effect of extensive flooding in Hull on the glycaemic control of patients with diabetes. Diabet Med (2011) 0.86
Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn (1996) 0.86
Calculated globulin (CG) as a screening test for antibody deficiency. Clin Exp Immunol (2014) 0.86
Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes? Minerva Endocrinol (2011) 0.85
Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf) (2007) 0.85
The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas. J Clin Pathol (2004) 0.85
Implications of new European Union driving regulations on patients with Type 1 diabetes who participated in the Diabetes Control and Complications Trial. Diabet Med (2013) 0.85
Erythropoetin treatment significantly alters measured glycated haemoglobin (HbA1c). Diabet Med (2008) 0.84
Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. Diabet Med (1987) 0.84
Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. Int J Oncol (1999) 0.84
Maternal serum screening for Down syndrome: are women's perceptions changing? BJOG (2007) 0.83
Response of estrogen receptor containing tumour cells to pure antiestrogens and the calmodulin inhibitor, calmidzolium chloride. J Steroid Biochem Mol Biol (2000) 0.83
Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. J Thromb Haemost (2008) 0.83
Clinical experience with the triple test for Down's syndrome screening. J Perinat Med (1991) 0.83
Evidence of gender bias when applying the new diagnostic criteria for myocardial infarction. Heart (2005) 0.83
Thyroidectomy does not cause globus pattern symptoms. J Laryngol Otol (2005) 0.83
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6. Br J Cancer (1999) 0.82
Cytokine expression in human anterior pituitary adenomas. Clin Endocrinol (Oxf) (1996) 0.82
Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus. J Clin Pathol (1986) 0.82
Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer (2002) 0.82
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabet Med (2008) 0.82
High-polyphenol chocolate reduces endothelial dysfunction and oxidative stress during acute transient hyperglycaemia in Type 2 diabetes: a pilot randomized controlled trial. Diabet Med (2013) 0.82
Angiotensin-converting enzyme (ACE): relationship to insulin-dependent diabetes and microangiopathy. Diabet Med (1987) 0.82
Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf) (2013) 0.82
Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) (2013) 0.81
The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab (2002) 0.81
Biological variation of cardiovascular risk factors in patients with diabetes. Diabet Med (2013) 0.81
Short-term glucose variability in healthy volunteers is not associated with raised oxidative stress markers. Diabetes Obes Metab (2012) 0.81
The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci (2003) 0.81